PDGFRB Gene Myeloproliferative Disorder, Chronic, with Eosinophilia Genetic Test in the UAE

Executive Summary & Core Metrics

This advanced genetic test employs Next-Generation Sequencing (NGS) to analyze the entire coding region of the PDGFRB gene, delivering diagnostic sensitivity exceeding 99.9% for myeloproliferative disorder with chronic eosinophilia. The test is processed under ISO 9001:2015 accreditation and DHA regulatory oversight, with integrated genetic counselling support.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

Test Summary: This advanced Next-Generation Sequencing (NGS) genetic test analyzes the entire coding region and flanking intronic regions of the PDGFRB gene to diagnose myeloproliferative disorder with chronic eosinophilia and guide targeted therapy with imatinib or other tyrosine kinase inhibitors.

Parameter	Our Test (PDGFRB NGS)	Closest Alternative (Sanger Sequencing Single Gene)
Technology	NGS – Full Gene & Flanking Introns	Sanger – Limited to Known Hotspots
Detection Rate	>99.9% Sensitivity including novel variants, deep intronic mutations, and large rearrangements	~95% for specific mutations; misses deep intronic & large rearrangements
Turnaround Time	3–4 Weeks	4–6 Weeks (often requires reflex to NGS)

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics specialist, I emphasise that a PDGFRB gene mutation finding must be interpreted alongside full clinical evaluation and bone marrow studies; this test is a powerful diagnostic tool, but treatment decisions require a holistic assessment. Our ISO-certified process ensures results you can trust, and our dedicated genetic counselling team is here to guide you every step.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Advisory: Medication & Clinical Interpretation

⚠ Critical Advisory

Do not discontinue prescribed medication (e.g., imatinib, corticosteroids) without consulting your doctor. A negative result does not exclude all haematological disorders; clinical correlation with peripheral blood smear, bone marrow biopsy, and cytogenetic studies is mandatory for accurate diagnosis.

Exclusion Criteria & Emergency Red Flags

Active severe infection or haemodynamic instability – postpone test until clinically stable.
Patients under 18 years must be accompanied by a legal guardian; consent per Federal Decree-Law No. 4 of 2016 on Medical Liability is strictly enforced.
If you experience sudden vision changes, extreme weakness, or uncontrolled bleeding, seek emergency care immediately and inform your haematologist.

Patient FAQ & Clinical Guidance

1. What does the PDGFRB NGS test detect?

The PDGFRB NGS test comprehensively identifies all clinically relevant genetic variants, including point mutations, small insertions or deletions, and copy-number changes within the PDGFRB gene, enabling precise diagnosis of eosinophilia-associated myeloid neoplasms and guiding targeted therapy selection.

2. How is the sample collected for this genetic test?

A simple peripheral whole blood draw (venous phlebotomy) or a single drop of blood on an FTA card is sufficient. Our VIP Mobile Phlebotomy team performs sterile, temperature-controlled cold-chain collection directly to the ISO-accredited laboratory, available daily from 8 AM to 11 PM.

3. What should I expect after receiving the result?

A dedicated genetic counsellor will explain your results in a complimentary telephonic session, correlating them with your clinical history and recommending any necessary follow-up with your haematologist or medical geneticist.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Security Framework: This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction. Patient consent and medical liability adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.

Corporate Oversight: DNA Labs UAE | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. ISO 9001:2015 certified. All clinical reviews are performed by DHA-registered specialists.

Clinical & Logistical Metadata

Test Name	PDGFRB Gene Myeloproliferative Disorder, Chronic, with Eosinophilia Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood (Venous Blood Draw or FTA Card)
Methodology Used	Next-Generation Sequencing (NGS) – Full Gene & Flanking Introns
ICD-10-CM Code	D47.1
LOINC Code	92819-5
DHA Facility License & Address	DNA Labs UAE \| License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE